Listing 1 - 2 of 2 |
Sort by
|
Choose an application
Rheumatoid arthritis is the most widespread chronic inflammatory disease in our regions. lt affects approximately 1% of the western population.Currently, the available treatments can, at best, stabilize the disease. Their goal is to minimize the harmful effects on the joints. Since the end of the 90's, biological therapies are available on the market. The development of these treatments relies on a better understanding of the pathophysiological mechanisms involved in the disease. Their efficiency, their therapeutic positioning, as well as their main side effects will be the focus of this work. La polyarthrite rhumatoïde est la pathologie inflammatoire chronique la plus répandue dans nos régions. Elle touche environ 1% de la population occidentale. À l'heure actuelle les traitements disponibles permettent au mieux une stabilisation de la maladie. Leur objectif est de minimiser les impacts néfastes sur les articulations. Depuis la fin des années 90 sont arrivés sur le marché les traitements dits biologiques.Le développement de ces thérapies repose sur la compréhension des mécanismes physiopathologiques impliqués dans la maladie. Leur efficacité, leur positionnement ainsi que leurs principaux effets indésirables seront traités à travers ce travail.
Choose an application
Outcome assessment (Medical care) --- Antirheumatic agents --- Rheumatoid arthritis --- Antirheumatic Agents --- Arthritis, Rheumatoid --- Abatacept --- Adalimumab --- Arthritis --- Clinical medicine --- Clinical trial --- Confounding --- Disease-modifying antirheumatic drug --- Etanercept --- Evidence-based medicine --- Golimumab --- Therapeutic use. --- Chemotherapy. --- therapeutic use. --- drug therapy.
Listing 1 - 2 of 2 |
Sort by
|